



Exelixis to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015

April 9, 2015

- Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 9, 2015-- Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2015 financial results will be released on Thursday, April 30, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the Company's website.

To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under Investors & Media. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 20896617 to join by phone.

A telephone replay will be available until 11:59 p.m. EDT on May 2, 2015. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 20896617. A webcast replay will also be archived on www.exelixis.com for one year.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's web site at www.exelixis.com.

Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor Relations and
Corporate Communications
shubbard@exelixis.com